The International CardiOncology Society An Update for 2014
Post on 04-Jan-2016
69 Views
Preview:
DESCRIPTION
Transcript
The International CardiOncology SocietyAn Update for 2014
Daniel J Lenihan, MDProfessor, Division of Cardiovascular MedicineDirector, Clinical ResearchVanderbilt University
The International CardiOncology SocietyAn Update
• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?
ICOS is:
• A collection of interested providers focused on improving cardiac health in cancer patients
• A mix of academic, practice, governmental, regulatory, and industry professionals
• Committed to our patients wherever they are
The International CardiOncology SocietyAn Update
• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?
We do things in many ways:• Day to day improvement in our practices• Monthly webinars available to all• Periodic presentations at major meetings• Annual ICOS congresses• Development of current “Best Practice”• Data review for ongoing early phase and late phase
clinical trials• Ongoing participation in major professional society
efforts• Ongoing individual and multicenter research• Consistent involvement with regulatory agencies in many
countries
The International CardiOncology SocietyAn Update
• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?
ICOS goals• Research
– Engage large databases– Cardiac safety endpoint
adjudication– Hypothesis testing
research
• Advocacy• Patients/families• Providers
• Education– Provider case review– Patient directed – Professional meetings– Industry/regulatory webinars– Trainee organization
• Be a Resource• Up to Date information• Identify Goals for the future• Provide innovation• Be an example of
collaboration
0
50
100
150
200
250
300
350
400
Chart TitleNumber of PUBMED articles on Cardio-Oncology
1971 2014
www.oncoreview.pl
The International CardiOncology SocietyAn Update
• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?
PREDICT Study: A multicenter study in Patients undergoing
anthRacycline-based chemotherapy to assess the Effectiveness of using biomarkers to Detect and Identify Cardiotoxicity and describe Treatment
Daniel J Lenihan, MDProfessor, Division of Cardiovascular MedicineVanderbilt UniversityCCOP Annual Meeting 2010
TotalAccrual:597 patients
Slamon D et al; NEJM 2011:365:1273-83
In the case of HER2+ breast cancer, treatment clearly benefitted the disease but came at a cost
0%0%0%
1-2
7%
28%
64%
0
20
40
60
80
100
2-4 4-6 6-8 8-10 10-12 >12
0%
(n=75) (n=35) (n=20) (n=12) (n=8) (n=7) (n=44)
months
Res
pon
der
s (%
)
D Cardinale, et al. JACC 2010, jan 26.
The effect of time for initiation of HF therapy and the percent of patients who
improve
In regards to Ischemic insults, we have a paradigm
Kloner et al, Circ 2001; p2981
Statin therapy prior to and during chemotherapy was protective
JACC 2012, p 2384
Prevention of Cardiotoxicity is possible
Bosch, X et al, JACC 2013, p 2355
Are there things on the cancer therapy horizon that could be concerning for
cardiomyopathy?
There is a balance between protein synthesis and degradation
Monte S. Willis, M.D., Ph.D., and Cam Patterson, M.D., M.B.A. NEJM 2013;368:455-64.
Dick,LR and Flemming,PE Drug Discovery Today ;15 (5/6) March 2010
The International CardiOncology SocietyAn Update
• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?
Kouri M et al. Circulation 2012
A Paradigm for Cardiology Oncology Cooperation
ICOS=
A public, private, patient, provider, regulatory, governmental PARTNERSHIP
www.icosna.org
top related